Caribou Biosciences (CRBU) Equity Ratio (2020 - 2025)
Caribou Biosciences (CRBU) has disclosed Equity Ratio for 6 consecutive years, with 0.75 as the latest value for Q2 2025.
- On a quarterly basis, Equity Ratio fell 9.66% to 0.75 in Q2 2025 year-over-year; TTM through Jun 2025 was 0.75, a 9.66% decrease, with the full-year FY2024 number at 0.81, down 5.28% from a year prior.
- Equity Ratio was 0.75 for Q2 2025 at Caribou Biosciences, down from 0.79 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.88 in Q4 2021 to a low of 0.3 in Q2 2021.
- A 5-year average of 0.75 and a median of 0.82 in 2022 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: soared 374.21% in 2022, then fell 9.66% in 2025.
- Caribou Biosciences' Equity Ratio stood at 0.88 in 2021, then decreased by 8.18% to 0.8 in 2022, then increased by 5.89% to 0.85 in 2023, then dropped by 5.28% to 0.81 in 2024, then decreased by 6.85% to 0.75 in 2025.
- Per Business Quant, the three most recent readings for CRBU's Equity Ratio are 0.75 (Q2 2025), 0.79 (Q1 2025), and 0.81 (Q4 2024).